Haite Biology: The company's intermediates and active pharmaceutical ingredient business have faced insufficient orders over the past two years due to intensified market competition, and are currently the company's main source of losses.

NightAirdropper · 2026-03-17T07:04:51+00:00

Hete Biotech stated that in recent years, intense competition and insufficient orders in the intermediates and active pharmaceutical ingredients business have become the main source of losses. The company is actively promoting this business and striving to achieve loss reduction and profitability turnaround.

NightAirdropper

2026-03-17 07:04:51

Abstract generation in progress

Meijing AI Express: An investor asked on the investor interaction platform: Are the intermediate and raw material drug businesses currently highly competitive? Is there a price war? Can they break even?

Haitai Biotech (300683.SZ) stated on March 13 on the investor interaction platform that in the past two years, due to increased market competition, orders for the intermediate and raw material drug businesses have been insufficient, and these are currently the company’s main sources of loss. The company is actively promoting the development of this business, has made some technological and product reserves, and is working to reduce losses and turn a profit.

(Reporter Wang Xiaobo)

Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Verify before use. Operate at your own risk.

Daily Economic News

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.